Candel Therapeutics (CADL) Interest Expenses (2022 - 2025)
Candel Therapeutics recorded quarterly Interest Expenses of $1.4 million in Q4 2025, up 779.5% quarter-over-quarter from $161000.0 in Q3 2025, and up 263.08% year-over-year from $390000.0 in Q4 2024.
Candel Therapeutics' Interest Expenses history runs 4 years deep, the most recent figure standing at $1.4 million for Q4 2025.
- In Q4 2025, Interest Expenses rose 263.08% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $2.1 million (up 1.39% YoY), while the FY2025 annual figure was $2.1 million, up 1.39% from the prior year.
- Interest Expenses came in at $1.4 million for Q4 2025 at Candel Therapeutics, up from $161000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $1.4 million in Q4 2025 to a low of $161000.0 in Q3 2025.
- A 4-year average of $555733.3 and a median of $567000.0 in 2024 frame the typical range for Interest Expenses.
- On a YoY basis, Interest Expenses climbed as much as 263.08% in 2025 and fell as far as 66.94% in 2025.
- Candel Therapeutics' Interest Expenses stood at $578000.0 in 2022, then gained by 16.44% to $673000.0 in 2023, then plunged by 42.05% to $390000.0 in 2024, then surged by 263.08% to $1.4 million in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $1.4 million, $161000.0, and $236000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | 1.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.42 Mn |
| Dec 31, 2025 | 1.42 Mn |
| Sep 30, 2025 | 161,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 236,000.00 |
| Jun 30, 2025 | 236,000.00 |
| Mar 31, 2025 | 306,000.00 |
| Mar 31, 2025 | 306,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Sep 30, 2024 | 487,000.00 |
| Sep 30, 2024 | 487,000.00 |
| Jun 30, 2024 | 567,000.00 |
| Jun 30, 2024 | 567,000.00 |
| Mar 31, 2024 | 646,000.00 |
| Mar 31, 2024 | 646,000.00 |
| Dec 31, 2023 | 673,000.00 |
| Dec 31, 2023 | 673,000.00 |
| Sep 30, 2023 | 669,000.00 |
| Sep 30, 2023 | 669,000.00 |
| Jun 30, 2023 | 644,000.00 |
| Jun 30, 2023 | 644,000.00 |
| Mar 31, 2023 | 609,000.00 |
| Mar 31, 2023 | 609,000.00 |
| Dec 31, 2022 | 578,000.00 |
| Dec 31, 2022 | 578,000.00 |
| Sep 30, 2022 | 519,000.00 |
| Sep 30, 2022 | 519,000.00 |
| Jun 30, 2022 | 435,000.00 |
| Jun 30, 2022 | 435,000.00 |